triclabendazole has been researched along with verapamil in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brennan, GP; Fairweather, I; Hoey, E; Meaney, M; Savage, J; Trudgett, A | 3 |
3 other study(ies) available for triclabendazole and verapamil
Article | Year |
---|---|
Effect of the P-glycoprotein inhibitor, R(+)-verapamil on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Benzimidazoles; Drug Resistance; Fasciola hepatica; Fascioliasis; Male; Microscopy, Electron, Scanning; Rats; Rats, Sprague-Dawley; Sulfoxides; Triclabendazole; Verapamil | 2013 |
Increased susceptibility of a triclabendazole (TCBZ)-resistant isolate of Fasciola hepatica to TCBZ following co-incubation in vitro with the P-glycoprotein inhibitor, R(+)-verapamil.
Topics: Animals; Anthelmintics; Benzimidazoles; Drug Resistance; Fasciola hepatica; Male; Microscopy, Electron, Scanning; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfoxides; Triclabendazole; Verapamil | 2013 |
Increased action of triclabendazole (TCBZ) in vitro against a TCBZ-resistant isolate of Fasciola hepatica following its co-incubation with the P-glycoprotein inhibitor, R(+)-verapamil.
Topics: Animals; Anthelmintics; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Calcium Channel Blockers; Drug Interactions; Fasciola hepatica; Male; Microscopy, Electron, Transmission; Rats; Rats, Sprague-Dawley; Sheep; Triclabendazole; Verapamil | 2013 |